Neuroendocrine Prostate Cancer (NEPC) Progressing from conventional prostatic adenocarcinoma: Factors associated with time to development of nepc and survival from NEPC Diagnosis-A systematic review and pooled analysis

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3383-3390

  Wang, Hai Tao ^a,b,c   Yao, Yan Hong ^a,b,c   Li, Bao Guo ^a,b,c   Tang, Yong ^a,c   Chang, Ji Wu ^d   Zhang, Jiao ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Research Group of Evidence based Clinical Oncology   (China)

^c KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^d Tianjin Inst of Urological Surgery   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DANUSERTIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CHEMORADIOTHERAPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; METASTASIS; NEUROENDOCRINE PROSTATE CANCER; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SURVIVAL TIME; SYSTEMATIC REVIEW; ADENOCARCINOMA; ADULT; AGED; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84908320059     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.3553     Document Type: Article

References (73)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. La Vecchia C, Bosetti C, Lucchini F, et al: Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21:1323-1360, 2010
3. Gué rin S, Hill C: Cancer epidemiology in France in 2010, comparison with the USA. Bull Cancer 97:47-54, 2010 [in French]
4. Mosquera JM, Beltran H, Park K, et al: Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15:1-10, 2013
5. Beltran H, Tagawa ST, Park K, et al: Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 30:e386-e389, 2012
6. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
7. Brawn PN, Speights VO: The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 59: 85-88, 1989
8. Ismail AHR, Landry F, Aprikian AG, et al: Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 51:117-125, 2002
9. Ito T, Yamamoto S, Ohno Y, et al: Upregulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 8:1221-1224, 2001
10. Shen R, Dorai T, Szaboles M, et al: Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormonedepleted medium. Urol Oncol 3:67-75, 1997
11. Wright ME, Tsai MJ, Aebersold R: Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17:1726-1737, 2003
12. Beltran H, Mosquera JM, Rubin MA: Neuroendocrine Prostate Cancer [M]//Prostate Cancer: A Comprehensive Perspective. London, United Kingdom, Springer, 2013, pp 277-282
13. Brownback KR, Renzulli J, Delellis R, et al: Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases. Indian J Urol 25:259-263, 2009
14. Tetu B, Ro JY, Ayala AG, et al: Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology 33:148-152, 1989
15. Kitamoto K, Hayashi T, Tamada S, et al: Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: A case report. Hinyokika kiyo 51:33-35, 2005 [in Japanese]
16. Yamamoto N, Kinoshita H, Inoue T, et al: Small cell carcinoma of the prostate: A case report. Hinyokika Kiyo 53:665-669, 2007 [in Japanese]
17. Fujii H, Morita S, Kimura Y, et al: Prostatic neuroendocrine carcinoma with priapism: A case report. Hinyokika Kiyo 57:337-339, 2011 [in Japanese]
18. Okada H, Gotoh A, Ogawa T, et al: Two cases of small cell carcinoma of the prostate. Scand J Urol Nephrol 30:503-508, 1996
19. Segawa N, Inamoto T, Ibuki N, et al: Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: A case report. Hinyokika Kiyo 56:49-54, 2010 [in Japanese]
20. Nguyen-Ho P, Nguyen GK, Villanueva RR: Small cell anaplastic carcinoma of the prostate: Report of a case with positive urine cytology. Diagn Cytopathol 10:159-161, 1994
21. Addeo A, Rinaldi C, Panades M: A case of small cell carcinoma of the prostate and review of the literature. Tumori 98:76e-78e, 2012
22. Aoki H, Ishidoya S, Ito A, et al: Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol 13:1254-1258, 2006
23. Dema A, Taban S, Borda A, et al: Neuroendocrine dedifferentiation of a prostate adenocarcinoma after hormonal treatment: A case study. Acta Endocrinologica (Buc) 7:535-544, 2011
24. Spieth ME, Lin YG, Nguyen TT: Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 27:11-17, 2002
25. Uemura KI, Nakagawa G, Chikui K, et al: A useful treatment for patients with advanced mixedtype small cell neuroendocrine carcinoma of the prostate: A case report. Oncol Lett 5:793-796, 2013
26. Venkatesh PK, Motwani B, Sherman N, et al: Metastatic pure small-cell carcinoma of prostate. Am J Med Sci 328:286-289, 2004
27. Yashi M, Terauchi F, Nukui A, et al: Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review. Urol Oncol 24:313-317, 2006
28. Yashi M, Muraishi O, Tokue A: Prostatic smallcell neuroendocrine carcinoma with disease progression monitored by measurement of serum progastrin-releasing peptide. BJU Int 86:1091-1092, 2000
29. Xiao L, Zhu XZ, Wang Y, et al: TMPRSS2-ERG gene fusion in metastatic prostate cancers: A study of fine needle aspiration specimens. Zhonghua Bing Li Xue Za Zhi 40:392-396, 2011 [in Chinese]
30. Brown JR, Wieczorek TJ, Shaffer K, et al: Small-cell cancers, and an unusual reaction to chemotherapy: Case 1, Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol 21: 2437-2438, 2003
31. Ciszewski A, Shackleton D, Beer TM: Longterm remission of metastatic small cell carcinoma of the prostate. Urology 71:546.e3-546.e4, 2008
32. Hu CH, Zhu HC, Liu XH, et al: Small cell carcinoma of the prostate recurred from prostatic adenocarcinoma after the androgen depletion treatment (report of 1 case and review of the literature) [in Chinese]. J Clin Urol 25:930-933, 2010
33. Tada K, Mitsui K, Mita A, et al: Two cases of neuroendocrine carcinoma of the prostate with positive urinary cytology. J Jpn Soc Clin Cytol 43:370-375, 2004 [in Japanese]
34. Oyama Y, Okugi H, Okazaki H, et al: Small cell carcinoma of the prostate diagnosed with the bladder invasion that appeared during maximum androgen blockade therapy. Jap J Clin Urol 64:659-663, 2010 [in Japanese]
35. Reichard C, Gilligan T, Watts KE, et al: A 45-year-old with neuroendocrine carcinoma of the prostate. Urology 81:714-716, 2013
36. Smith DC, Tucker JA, Trump DL: Hypercalcemia and neuroendocrine carcinoma of the prostate: A report of three cases and a review of the literature. J Clin Oncol 10:499-505, 1992
37. Schron DS, Gipson T, Mendelsohn G: The histogenesis of small cell carcinoma of the prostate: An immunohistochemical study. Cancer 53:2478-2480, 1984
38. Huang IS, Huang WJS, Lin ATL, et al: Small cell carcinoma of the prostate: Three case reports and a literature review. Urol Sci 10.1016/j.urols.2013.05.003
39. Clouston PD, Saper CB, Arbizu T, et al: Paraneoplastic cerebellar degeneration: III, Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 42:1944-1950, 1992
40. McMahon GT, Blake MA, Wu CL: Case records of the Massachusetts General Hospital: Case 1-2010-A 75-year-old man with hypertension, hyperglycemia, and edema. N Engl J Med 362:156-166, 2010
41. Nimalasena S, Freeman A, Harland S: Paraneoplastic Cushing's syndrome in prostate cancer: A difficult management problem. BJU Int 101:424-427, 2008
42. Rajec J, Mego M, Sycova-Mila Z, et al: Paraneoplastic Cushing's syndrome as the first sign of progression of prostate cancer. Bratisl Lek Listy 109:362-363, 2008
43. Tanaka M, Suzuki Y, Takaoka K, et al: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 8:431-436, 2001
44. Fernandes RC, Matsushita MM, Mauad T, et al: Prostate carcinoma with neuroendocrine differentiation: Case report and literature review. Revista do Hospital das Clínicas 56:153-158, 2001
45. Huang WH, Wang JS, Wu TT: Small-cell carcinoma of the prostate: A case report. JTUA 14:144-146, 2003
46. Komiya A, Yasuda K, Nozaki T, et al: Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma. Oncol Lett 5:53-56, 2013
47. Wenk RE, Bhagavan BS, Levy R, et al: Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 40:773-778, 1977
48. Sö zen S, Ü ner A, Alkibay T: Small cell cracinoma of the prostate: Report of two cases. Turk J Cancer 30:131-134, 2000
49. Christopher ME, Seftel AD, Sorenson K, et al: Small cell carcinoma of the genitourinary tract: An immunohistochemical, electron microscopic and clinicopathological study. J Urol 146:382-388, 1991
50. Moratalla Charcos LM, Pastor Navarro T, Cortes Vizcaino V, et al: Large-cell neuroendocrine carcinoma of prostate: Case report. Arch Esp Urol 66:368-371, 2013
51. Wynn SS, Nagabundi S, Koo J, et al: Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med 124:1074-1076, 2000
52. Vuitch MF, Mendelsohn G: Relationship of ectopic ACTH production to tumor differentiation: A morphologic and immunohistochemical study of prostatic carcinoma with Cushing's syndrome. Cancer 47:296-299, 1981
53. Matschke J, Erbersdobler A: Extensive cerebral metastases from neuroendocrine carcinoma of the prostate. Virchows Arch 444:202-203, 2004
54. Schneider A, Kollias A, Woziwodzki J, et al: Testicular metastasis of a metachronous small cell neuroendocrinic prostate cancer after anti-hormonal therapy of a prostatic adenocarcinoma: Case report and literature review. Urologe A 45:75-80, 2006 [in German]
55. Caraway NP, Fanning CV, Shin HJ, et al: Metastatic small-cell carcinoma of the prostate diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol 19:12-16, 1998
56. Miyoshi Y, Uemura H, Kitami K, et al: Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int 88:982-983, 2001
57. Rubenstein JH, Katin MJ, Mangano MM, et al: Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 20:376-380, 1997
58. Ohshima M, Ohyama N, Hiramatsu T, et al: Primary small cell carcinoma of prostate: A case report and a review of 32 cases in Japanese literature. J Nissei Hosp 27:124-130, 1999 [in Japanese]
59. Evans AJ, Humphrey PA, Belani J, et al: Large cell neuroendocrine carcinoma of prostate: A clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 30:684-693, 2006
60. Cai G, Ramdall RB, Levine P, et al: Fine-needle aspiration of metastatic prostatic neuroendocrine carcinomas: Cytomorphologic and immunophenotypic features. Diagn Cytopathol 36:545-549, 2008
61. Otsuka Y, Kubota H, Issey O, et al: Local radiation therapy was effective against one case of prostate small cell carcinoma that occurred in the endocrine therapy of advanced prostate cancer. Urol Surg 22:398-399, 2009 [in Japanese]
62. Nadig SN, Deibler AR, El Salamony TM, et al: Small cell carcinoma of the prostate: An underrecognized entity. Can J Urol 8:1207-1210, 2001
63. Beltran H, Rickman DS, Park K, et al: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487-495, 2011
64. Eble JN, Sauter G, Epstein JI, et al (eds): Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs: World Health Organisation Classification of Tumours. Lyon, France, IARC Press, 2004
65. Epstein JI, Amin MB, Beltran H, et al: Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-767, 2014
66. Wang W, Epstein JI: Small cell carcinoma of the prostate: A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 32:65-71, 2008
67. Aparicio AM, Harzstark AL, Corn PG, et al: Platinum-based chemotherapy for variant castrateresistant prostate cancer. Clinical Cancer Res 19: 3621-3630, 2013
68. Steineck G, Reuter V, Kelly WK, et al: Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 41:668-674, 2002
69. Nadal R, Schweizer M, Kryvenko ON, et al: Small cell carcinoma of the prostate. Nat Rev Urol 11:213-219, 2014
70. Papandreou CN, Daliani DD, Thall PF, et al: Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072-3080, 2002
71. Bunn PA Jr, Carney DN: Overview of chemotherapy for small cell lung cancer. Semin Oncol S 7:69-74, 1997
72. Psyrri A, Murren J: Small cell lung cancer: Strategies to optimize chemotherapy response. Cancer J S 1:28-34, 2001
73. Lapuk AV, Wu C, Wyatt AW, et al: From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 227:286-297, 2012